Sonnet BioTherapeutics I...

NASDAQ: SONN · Real-Time Price · USD
3.53
-0.23 (-6.12%)
At close: Aug 15, 2025, 3:59 PM
3.50
-0.85%
After-hours: Aug 15, 2025, 07:58 PM EDT

Sonnet BioTherapeutics Income Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Revenue
n/a n/a 1M n/a n/a n/a 18.63K 37.26K 36.85K 36.45K 37.26K 62.75K 62.07K 95.32K 129.8K 483.63K n/a n/a n/a
Cost of Revenue
n/a 22.09K 22.19K 21.61K 21.04K 20.5K 19.97K 19.47K 18.98K 18.87K 18.43K 17.93K 5.65M 6.41M 25.45K 5.04M 24.07K 23.51K 3.87M
Gross Profit
n/a -22.09K 1M -21.61K -21.04K -20.5K -1.35K 17.79K 17.87K 17.57K 18.82K 44.83K -5.59M -6.31M 104.35K -4.55M -24.07K -23.51K -3.87M
Operating Income
-3.81M -4.23M -2.85M -3.17M -3.53M -3.87M -1.28M -3.6M -3.92M -5.66M -5.61M -7.38M -7.87M -8.21M -6.21M -6.95M -6.24M -6.04M -5.86M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-3.78M -3.49M -3M -3.13M -3.51M 365.43K -1.17M -3.68M -3.95M -5.67M -5.54M -7.44M -7.88M -8.21M -6.2M -6.95M -6.12M -6.04M -5.88M
Net Income
-3.78M -3.49M -3.16M -3.13M -3.51M 365.43K -1.17M -3.68M -3.95M -5.67M -5.54M -7.49M -7.89M -8.21M -6.17M -6.95M -6.12M -6.04M -5.88M
Selling & General & Admin
1.38M 2.34M 1.96M 1.97M 1.8M 1.7M 653.46K 1.79M 1.54M 1.88M 1.9M 2.32M 2.28M 1.9M 2.08M 2.39M 2.35M 2.2M 2M
Research & Development
2.43M 1.88M 1.89M 1.2M 1.73M 2.17M 644.04K 1.84M 2.41M 3.82M 3.75M 5.12M 5.65M 6.41M 4.27M 5.04M 3.89M 3.84M 3.87M
Other Expenses
n/a n/a n/a -21.61K n/a 727.00 -497 -19.47K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
3.81M 4.23M 3.85M 3.15M 3.53M 3.87M 1.3M 3.62M 3.95M 5.7M 5.65M 7.44M 7.93M 8.31M 6.34M 7.43M 6.24M 6.04M 5.86M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 58.38K 9.79K n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
n/a 4.23M 3.85M 3.17M 3.53M 3.87M 1.3M 3.64M 3.95M 5.7M 5.65M 7.44M 7.93M 8.31M 6.34M 7.43M 6.24M 6.04M 5.86M
Income Tax Expense
n/a n/a 158.4K n/a n/a n/a n/a n/a 31.43K 4.61K n/a 58.38K 9.79K -1.72K -27.94K 5.19K 1.51K 2.08K 13.25K
Shares Outstanding (Basic)
3.97M 3.92M 2.02M 650.28K 629.69K 577.21K 474.72K 218.8K 166.91K 93.83K 39.32K 25.45K 24.61K 24.47K 24.47K 9.55K 9.13K 7.61K 6.99K
Shares Outstanding (Diluted)
3.97M 3.92M 2.02M 650.28K 629.69K 577.21K 474.72K 218.8K 166.91K 93.83K 39.32K 25.45K 24.61K 24.47K 24.47K 9.55K 9.13K 7.61K 6.99K
EPS (Basic)
-0.95 -0.89 -1.56 -4.81 -5.57 0.63 -2.46 -16.8 -23.65 -60.4 -140.94 -292.17 -320.15 -335.45 -253.42 -728.19 -669.67 -793.93 -841.04
EPS (Diluted)
-0.95 -0.89 -1.56 -4.81 -5.57 0.63 -2.46 -16.8 -23.65 -60.4 -140.94 -292.17 -320.15 -335.45 -253.42 -728.19 -669.67 -793.93 -841.04
EBITDA
-3.81M -4.21M -2.83M -3.15M -3.51M -3.85M -1.26M -3.58M -3.9M -5.65M -5.59M -7.36M -7.84M -8.18M -6.19M -6.92M -6.22M -6.01M -5.84M
EBIT
n/a -4.23M -2.85M -3.17M -3.53M -3.87M -1.28M -3.6M -3.92M -5.66M -5.61M -7.38M -7.87M -8.21M -6.21M -6.95M -6.24M -6.04M -5.86M
Depreciation & Amortization
n/a 22.09K 22.19K 21.61K 21.04K 20.5K 19.97K 19.47K 18.98K 18.87K 18.43K 17.93K 23.69K 26.19K 25.45K 24.79K 24.07K 23.51K 22.8K